Cytokinetics, Incorporated (CYTK)

NASDAQ: CYTK · IEX Real-Time Price · USD
48.98
-10.25 (-17.31%)
At close: May 23, 2024, 4:00 PM
48.93
-0.05 (-0.10%)
Pre-market: May 24, 2024, 9:10 AM EDT
-17.31%
Market Cap 5.14B
Revenue (ttm) 3.75M
Net Income (ttm) -530.60M
Shares Out 104.85M
EPS (ttm) -5.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,397,772
Open 49.25
Previous Close 59.23
Day's Range 47.59 - 50.24
52-Week Range 25.98 - 110.25
Beta 0.72
Analysts Buy
Price Target 80.13 (+63.6%)
Earnings Date May 8, 2024

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that i... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 29, 2004
Employees 423
Stock Exchange NASDAQ
Ticker Symbol CYTK
Full Company Profile

Financial Performance

In 2023, Cytokinetics's revenue was $7.53 million, a decrease of -92.04% compared to the previous year's $94.59 million. Losses were -$526.24 million, 35.3% more than in 2022.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for CYTK stock is "Buy." The 12-month stock price forecast is $80.13, which is an increase of 63.60% from the latest price.

Price Target
$80.13
(63.60% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cytokinetics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,803,922 shares of its common...

1 day ago - GlobeNewsWire

Cytokinetics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $500 milli...

1 day ago - GlobeNewsWire

Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

Deal Provides Cytokinetics with Diversified Access to Capital as Company Advances Its Specialty Cardiology Franchise Deal Provides Cytokinetics with Diversified Access to Capital as Company Advances I...

1 day ago - GlobeNewsWire

Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology

SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscl...

7 days ago - GlobeNewsWire

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024

SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten at the European Society of Cardiology Co...

9 days ago - GlobeNewsWire

Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress

Analyses of SEQUOIA-HCM Elaborate on Dosing and Measures of Safety During Treatment with Aficamten Results from Cardiopulmonary Exercise Testing Showed Improvement in Exercise Performance were Strongl...

11 days ago - GlobeNewsWire

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine

Statistically Significant and Clinically Meaningful Improvements Observed in Primary Efficacy Endpoint and All Secondary Endpoints; Results Consistent Across All Prespecified Subgroups

11 days ago - GlobeNewsWire

Cytokinetics Reports First Quarter 2024 Financial Results

Primary Results and Two Additional Analyses from SEQUOIA-HCM to be Presented in a Late-Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress

15 days ago - GlobeNewsWire

Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586

Data Support Advancement to Phase 2 Clinical Trial in Patients with Heart Failure  with Preserved Ejection Fraction Expected to Begin in Q4 2024

16 days ago - GlobeNewsWire

Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM (Clinical Evaluation of Dosing with A ficamten to Reduce Obstruct...

16 days ago - GlobeNewsWire

Cytokinetics to Hold Annual Meeting of Stockholders

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 15, 2024 ...

16 days ago - GlobeNewsWire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 30, 2024 it granted stock options to purchase an aggregate of 29,6...

21 days ago - GlobeNewsWire

Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

SOUTH SAN FRANCISCO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will host an investor event and conference call on May 13, 2024 at 4:00 PM ...

24 days ago - GlobeNewsWire

Cytokinetics to Announce First Quarter Results on May 8, 2024

SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM...

4 weeks ago - GlobeNewsWire

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

6 weeks ago - Market Watch

Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy

6 weeks ago - GlobeNewsWire

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session

Treatment with Aficamten for 48 Weeks is Associated with Improvements in Clinical Efficacy Endpoints, NYHA Class and Cardiac Biomarkers, Structure and Function Treatment with Aficamten for 48 Weeks is...

7 weeks ago - GlobeNewsWire

Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to pa...

7 weeks ago - GlobeNewsWire

Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session

SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 73rd Annual Scientifi...

2 months ago - GlobeNewsWire

Cytokinetics to Participate in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor confere...

2 months ago - GlobeNewsWire

Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day

SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is joining the European Organisation for Rare Diseases (EURORDIS) and t...

3 months ago - GlobeNewsWire

Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials

Grant Funding Provided by Cytokinetics to Each Organization to Help Increase Clinical Trial Engagement Among Historically Underrepresented Groups Grant Funding Provided by Cytokinetics to Each Organiz...

3 months ago - GlobeNewsWire

Cytokinetics Reports Fourth Quarter 2023 Financial Results

Topline Results from SEQUOIA-HCM Announced in December Showed Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint and Improvements in All Secondary Endpoints

3 months ago - GlobeNewsWire

Cytokinetics to Announce Fourth Quarter Results on February 27, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at 4...

3 months ago - GlobeNewsWire

Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to par...

3 months ago - GlobeNewsWire